1
|
Hernández-Gil J, Chow CY, Chatras H, de Souza França PD, Samuels ZV, Cornejo M, King GF, Lewis JS, Reiner T, Gonzales J. Development and Validation of Nerve-Targeted Bacteriochlorin Sensors. J Am Chem Soc 2023; 145:14276-14287. [PMID: 37339504 PMCID: PMC11443384 DOI: 10.1021/jacs.3c02520] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/22/2023]
Abstract
We report an innovative approach to producing bacteriochlorins (bacs) via formal cycloaddition by subjecting a porphyrin to a trimolecular reaction. Bacs are near-infrared probes with the intrinsic ability to serve in multimodal imaging. However, despite their ability to fluoresce and chelate metal ions, existing bacs have thus offered limited ability to label biomolecules for target specificity or have lacked chemical purity, limiting their use in bio-imaging. In this work, bacs allowed a precise and controlled appending of clickable linkers, lending the porphyrinoids substantially more chemical stability, clickability, and solubility, rendering them more suitable for preclinical investigation. Our bac probes enable the targeted use of biomolecules in fluorescence imaging and Cerenkov luminescence for guided intraoperative imaging. Bacs' capacity for chelation provides opportunities for use in non-invasive positron emission tomography/computed tomography. Herein, we report the labeling of bacs with Hs1a, a (NaV1.7)-sodium-channel-binding peptide derived from the Chinese tarantula Cyriopagopus schmidti to yield Bac-Hs1a and radiolabeled Hs1a, which shuttles our bac sensor(s) to mouse nerves. In vivo, the bac sensor allowed us to observe high signal-to-background ratios in the nerves of animals injected with fluorescent Bac-Hs1a and radiolabeled Hs1a in all imaging modes. This study demonstrates that Bac-Hs1a and [64Cu]Cu-Bac-Hs1a accumulate in peripheral nerves, providing contrast and utility in the preclinical space. For the chemistry and bio-imaging fields, this study represents an exciting starting point for the modular manipulation of bacs, their development and use as probes for diagnosis, and their deployment as formidable multiplex nerve-imaging agents for use in routine imaging experiments.
Collapse
Affiliation(s)
- Javier Hernández-Gil
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B3000 Leuven, Belgium
- Instituto de Tecnología Química, Universitat Politècnica de València, Consejo Superior de Investigaciones Científicas, Valencia E-46022, Spain
| | - Chun Yuen Chow
- Institute for Molecular Bioscience and Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Research, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Hugo Chatras
- Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115, United States
| | - Paula Demétrio de Souza França
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Otorhinolaryngology and Head and Neck Surgery, Federal University of São Paulo, São Paulo, SP 04020-041, Brazil
| | - Zachary V. Samuels
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Mike Cornejo
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Glenn F. King
- Institute for Molecular Bioscience and Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Research, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Jason S. Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Pharmacology, Weill-Cornell Medical College, New York, New York 10065, United States
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Radiology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Pharmacology, Weill-Cornell Medical College, New York, New York 10065, United States
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Radiology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Junior Gonzales
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115, United States
- Center for Gene Regulation in Health and Disease, Cleveland, Ohio 44115, United States
| |
Collapse
|
2
|
Deda DK, Iglesias BA, Alves E, Araki K, Garcia CRS. Porphyrin Derivative Nanoformulations for Therapy and Antiparasitic Agents. Molecules 2020; 25:molecules25092080. [PMID: 32365664 PMCID: PMC7249045 DOI: 10.3390/molecules25092080] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/21/2020] [Accepted: 04/22/2020] [Indexed: 12/12/2022] Open
Abstract
Porphyrins and analogous macrocycles exhibit interesting photochemical, catalytic, and luminescence properties demonstrating high potential in the treatment of several diseases. Among them can be highlighted the possibility of application in photodynamic therapy and antimicrobial/antiparasitic PDT, for example, of malaria parasite. However, the low efficiency generally associated with their low solubility in water and bioavailability have precluded biomedical applications. Nanotechnology can provide efficient strategies to enhance bioavailability and incorporate targeted delivery properties to conventional pharmaceuticals, enhancing the effectiveness and reducing the toxicity, thus improving the adhesion to the treatment. In this way, those limitations can be overcome by using two main strategies: (1) Incorporation of hydrophilic substituents into the macrocycle ring while controlling the interaction with biological systems and (2) by including them in nanocarriers and delivery nanosystems. This review will focus on antiparasitic drugs based on porphyrin derivatives developed according to these two strategies, considering their vast and increasing applications befitting the multiple roles of these compounds in nature.
Collapse
Affiliation(s)
- Daiana K. Deda
- Department of Fundamental Chemistry, Institute of Chemistry, University of Sao Paulo, Av. Prof. Lineu Prestes 748, Butanta, Sao Paulo, SP 05508-000, Brazil; (D.K.D.); (K.A.)
| | - Bernardo A. Iglesias
- Bioinorganic and Porphyrinoid Materials Laboratory, Department of Chemistry, Federal University of Santa Maria, Av. Roraima 1000, Camobi, Santa Maria, RS 97105-900, Brazil;
| | - Eduardo Alves
- Department of Life Science, Imperial College London, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK;
| | - Koiti Araki
- Department of Fundamental Chemistry, Institute of Chemistry, University of Sao Paulo, Av. Prof. Lineu Prestes 748, Butanta, Sao Paulo, SP 05508-000, Brazil; (D.K.D.); (K.A.)
| | - Celia R. S. Garcia
- Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, Sao Paulo, SP 05508-900, Brazil
- Correspondence: ; Tel.: +55-11-2648-0954
| |
Collapse
|
3
|
Aguilar-Ortíz E, Jalilian AR, Ávila-Rodríguez MA. Porphyrins as ligands for 64copper: background and trends. MEDCHEMCOMM 2018; 9:1577-1588. [PMID: 30429966 PMCID: PMC6194497 DOI: 10.1039/c8md00263k] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Accepted: 08/17/2018] [Indexed: 12/13/2022]
Abstract
Porphyrins and 64Cu have emerged as a novel synergic option for applications in PET molecular imaging. Both the characteristics and photophysical properties of macrocyclic porphyrins and the relatively long half-life of the copper isotope, in addition to the increased tumor-specific uptake of porphyrins compared to normal cells, make this complex an attractive option not only for diagnosis but also for therapeutic applications. Herein, we present an overview of the latest results on the development of PET agents based on porphyrins and 64Cu, including methods used to improve the selectivity of these macrocycles when conjugated with biological units such as monoclonal antibodies, peptides or proteins.
Collapse
Affiliation(s)
- Edgar Aguilar-Ortíz
- Unidad Radiofarmacia-Ciclotrón , División de Investigación , Facultad de Medicina , Universidad Nacional Autónoma de México , 04510 Cd. Mx. , Mexico . ;
| | - Amir R Jalilian
- Department of Nuclear Sciences and Applications , International Atomic Energy Agency (IAEA) , Vienna , Austria
| | - Miguel A Ávila-Rodríguez
- Unidad Radiofarmacia-Ciclotrón , División de Investigación , Facultad de Medicina , Universidad Nacional Autónoma de México , 04510 Cd. Mx. , Mexico . ;
| |
Collapse
|
4
|
Luo Y, Wu H, Feng C, Xiao K, Yang X, Liu Q, Lin TY, Zhang H, Walton JH, Ajena Y, Hu Y, Lam KS, Li Y. "One-Pot" Fabrication of Highly Versatile and Biocompatible Poly(vinyl alcohol)-porphyrin-based Nanotheranostics. Am J Cancer Res 2017; 7:3901-3914. [PMID: 29109786 PMCID: PMC5667413 DOI: 10.7150/thno.20190] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 07/07/2017] [Indexed: 02/05/2023] Open
Abstract
Nanoparticle-based theranostic agents have emerged as a new paradigm in nanomedicine field for integration of multimodal imaging and therapeutic functions within a single platform. However, the clinical translation of these agents is severely limited by the complexity of fabrication, long-term toxicity of the materials, and unfavorable biodistributions. Here we report an extremely simple and robust approach to develop highly versatile and biocompatible theranostic poly(vinyl alcohol)-porphyrin nanoparticles (PPNs). Through a “one-pot” fabrication process, including the chelation of metal ions and encapsulation of hydrophobic drugs, monodispersenanoparticle could be formed by self-assembly of a very simple and biocompatible building block (poly(vinyl alcohol)-porphyrin conjugate). Using this approach, we could conveniently produce multifunctional PPNs that integrate optical imaging, positron emission tomography (PET), photodynamic therapy (PDT), photothermal therapy (PTT) and drug delivery functions in one formulation. PPNs exhibited unique architecture-dependent fluorescence self-quenching, as well as photodynamic- and photothermal- properties. Near-infrared fluorescence could be amplified upon PPN dissociation, providing feasibility of low-background fluorescence imaging. Doxorubicin (DOX)-loaded PPNs achieved 53 times longer half-life in blood circulation than free DOX. Upon irradiation by near infrared light at a single excitation wavelength, PPNs could be activated to release reactive oxygen species, heat and drugs simultaneously at the tumor sites in mice bearing tumor xenograft, resulting in complete eradication of tumors. Due to their organic compositions, PPNs showed no obvious cytotoxicity in mice via intravenous administration during therapeutic studies. This highly versatile and multifunctional PPN theranostic nanoplatform showed great potential for the integration of multimodal imaging and therapeutic functions towards personalized nanomedicine against cancers.
Collapse
|
5
|
Nuclear medicine for photodynamic therapy in cancer: Planning, monitoring and nuclear PDT. Photodiagnosis Photodyn Ther 2017; 18:236-243. [PMID: 28300723 DOI: 10.1016/j.pdpdt.2017.03.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 02/27/2017] [Accepted: 03/09/2017] [Indexed: 12/16/2022]
Abstract
Photodynamic therapy (PDT) is a modality with promising results for the treatment of various cancers. PDT is increasingly included in the standard of care for different pathologies. This therapy relies on the effects of light delivered to photosensitized cells. At different stages of delivery, PDT requires imaging to plan, evaluate and monitor treatment. The contribution of molecular imaging in this context is important and continues to increase. In this article, we review the contribution of nuclear medicine imaging in oncology to PDT for planning and therapeutic monitoring purposes. Several solutions have been proposed to plan PDT from nuclear medicine imaging. For instance, photosensitizer biodistribution has been evaluated with a radiolabeled photosensitizer or with conventional radiopharmaceuticals on positron emission tomography. The effects of PDT delivery have also been explored with specific SPECT or PET radiopharmaceuticals to evaluate the effects on cells (apoptosis, necrosis, proliferation, metabolism) or vascular damage. Finally, the synergy between photosensitizers and radiopharmaceuticals has been studied considering the Cerenkov effect to activate photosensitized cells.
Collapse
|
6
|
Zhao J, Zhou M, Li C. Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy. Cancer Nanotechnol 2016; 7:9. [PMID: 27909463 PMCID: PMC5112292 DOI: 10.1186/s12645-016-0022-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 11/02/2016] [Indexed: 12/11/2022] Open
Abstract
Radiotherapy has been, and will continue to be, a critical modality to treat cancer. Since the discovery of radiation-induced cytotoxicity in the late 19th century, both external and internal radiation sources have provided tremendous benefits to extend the life of cancer patients. Despite the dramatic improvement of radiation techniques, however, one challenge persists to limit the anti-tumor efficacy of radiotherapy, which is to maximize the deposited dose in tumor while sparing the rest of the healthy vital organs. Nanomedicine has stepped into the spotlight of cancer diagnosis and therapy during the past decades. Nanoparticles can potentiate radiotherapy by specifically delivering radionuclides or radiosensitizers into tumors, therefore enhancing the efficacy while alleviating the toxicity of radiotherapy. This paper reviews recent advances in synthetic nanoparticles for radiotherapy and radiosensitization, with a focus on the enhancement of in vivo anti-tumor activities. We also provide a brief discussion on radiation-associated toxicities as this is an area that, up to date, has been largely missing in the literature and should be closely examined in future studies involving nanoparticle-mediated radiosensitization.
Collapse
Affiliation(s)
- Jun Zhao
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, TX 77054 USA
| | - Min Zhou
- Institute of Translational Medicine, Zhejiang University, Hangzhou, 310009 Zhejiang China
| | - Chun Li
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, TX 77054 USA
| |
Collapse
|
7
|
Hervella P, Parra E, Needham D. Encapsulation and retention of chelated-copper inside hydrophobic nanoparticles: Liquid cored nanoparticles show better retention than a solid core formulation. Eur J Pharm Biopharm 2016; 102:64-76. [DOI: 10.1016/j.ejpb.2016.02.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Revised: 01/26/2016] [Accepted: 02/23/2016] [Indexed: 10/22/2022]
|
8
|
|
9
|
Bryden F, Savoie H, Rosca EV, Boyle RW. PET/PDT theranostics: synthesis and biological evaluation of a peptide-targeted gallium porphyrin. Dalton Trans 2015; 44:4925-32. [DOI: 10.1039/c4dt02949f] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In pursuit of the goal of a molecular theranostic suitable for use as a PET radiotracer and a photosensitiser for PDT, a novel 68Ga radiolabelled peptide–porphyrin conjugate targeting the α6β1-integrin has been developed.
Collapse
|
10
|
Evaluation of labelling conditions, quality control and biodistribution study of 99mTc-5-aminolevulinic acid (5-ALA): a potential liver imaging agent. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3014-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Waghorn PA. Radiolabelled porphyrins in nuclear medicine. J Labelled Comp Radiopharm 2013; 57:304-9. [PMID: 24353174 DOI: 10.1002/jlcr.3166] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 10/29/2013] [Indexed: 11/09/2022]
Abstract
Amongst tumour-specific substances, hematoporphyrin and synthetic porphyrin derivatives have been widely investigated to identify and delineate neoplastic and malignant tissue. Whilst the tumour localization exhibited by selected porphyrin species has been exploited through photodynamic therapy, several examples of porphyrin derivatives with varied peripheral functionality have been radiolabelled with the aim of developing porphyrin-based nuclear imaging and therapeutic agents. In this review, we look at the approaches and advances in the preparation and uses of such radiolabelled agents for imaging and therapy.
Collapse
Affiliation(s)
- Philip A Waghorn
- CR-UK/MRC Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Oxford, OX3 7LE, UK; Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK
| |
Collapse
|
12
|
Liu TW, MacDonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Zheng G. Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS NANO 2013; 7:4221-32. [PMID: 23544841 PMCID: PMC3667620 DOI: 10.1021/nn400669r] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 04/01/2013] [Indexed: 05/18/2023]
Abstract
Prostate cancer is the most common cancer among men and the second cause of male cancer-related deaths. There are currently three critical needs in prostate cancer imaging to personalize cancer treatment: (1) accurate intraprostatic imaging for multiple foci and extra-capsular extent; (2) monitoring local and systemic treatment response and predicting recurrence; and (3) more sensitive imaging of occult prostate cancer bone metastases. Recently, our lab developed porphysomes, inherently multimodal, all-organic nanoparticles with flexible and robust radiochemistry. Herein, we validate the first in vivo application of (64)Cu-porphysomes in clinically relevant orthotopic prostate and bony metastatic cancer models. We demonstrate clear multimodal delineation of orthotopic tumors on both the macro- and the microscopic scales (using both PET and fluorescence) and sensitively detected small bony metastases (<2 mm). The unique and multifaceted properties of porphysomes offers a promising all-in-one prostate cancer imaging agent for tumor detection and treatment response/recurrence monitoring using both radionuclide- and photonic-based strategies.
Collapse
Affiliation(s)
- Tracy W. Liu
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON Canada M5G 2M9
| | - Thomas D. MacDonald
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Pharmaceutical Sciences, University of Toronto, 144 College Street, Toronto, ON Canada M5S 3M2
| | - Cheng S. Jin
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Pharmaceutical Sciences, University of Toronto, 144 College Street, Toronto, ON Canada M5S 3M2
| | - Joseph M. Gold
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON Canada M5G 2M9
| | - Robert G. Bristow
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Princess Margaret Cancer Center, UHN, 610 University Avenue, Toronto, ON Canada M5T 2M9
| | - Brian C. Wilson
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON Canada M5G 2M9
| | - Gang Zheng
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON Canada M5G 2M9
- Department of Pharmaceutical Sciences, University of Toronto, 144 College Street, Toronto, ON Canada M5S 3M2
- Address correspondence to
| |
Collapse
|
13
|
Mukai H, Wada Y, Watanabe Y. The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents. Ann Nucl Med 2013; 27:625-39. [DOI: 10.1007/s12149-013-0728-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Accepted: 04/05/2013] [Indexed: 10/26/2022]
|
14
|
Liu TW, MacDonald TD, Shi J, Wilson BC, Zheng G. Intrinsically Copper-64-Labeled Organic Nanoparticles as Radiotracers. Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201206939] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
15
|
Liu TW, MacDonald TD, Shi J, Wilson BC, Zheng G. Intrinsically copper-64-labeled organic nanoparticles as radiotracers. Angew Chem Int Ed Engl 2012; 51:13128-31. [PMID: 23154923 DOI: 10.1002/anie.201206939] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2012] [Indexed: 12/24/2022]
Abstract
PET friendly: labels for PET imaging are incorporated into completely organic porphysomes by using a fast (30 min), one-pot, high-yielding (>95 %) procedure to produce highly stable (>48 h) radiolabeled nanoparticles that show the highest specific activity ever reported for a (64) Cu-labeled nanoparticle. These (64) Cu-porphysomes can be accurately and noninvasively tracked in vivo.
Collapse
Affiliation(s)
- Tracy W Liu
- Ontario Cancer Institute, Campbell Family Institute for Cancer Research, UHN, Canada
| | | | | | | | | |
Collapse
|
16
|
Josefsen LB, Boyle RW. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2012; 2:916-66. [PMID: 23082103 PMCID: PMC3475217 DOI: 10.7150/thno.4571] [Citation(s) in RCA: 384] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Accepted: 08/10/2012] [Indexed: 02/07/2023] Open
Abstract
Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types. Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms. The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.
Collapse
|
17
|
Zhang Y, Lovell JF. Porphyrins as theranostic agents from prehistoric to modern times. Theranostics 2012; 2:905-15. [PMID: 23082102 PMCID: PMC3475213 DOI: 10.7150/thno.4908] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2012] [Accepted: 08/17/2012] [Indexed: 01/01/2023] Open
Abstract
Long before humans roamed the planet, porphyrins in blood were serving not only as indispensable oxygen carriers, but also as the bright red contrast agent that unmistakably indicates injury sites. They have proven valuable as whole body imaging modalities have emerged, with endogenous hemoglobin porphyrins being used for new approaches such as functional magnetic resonance imaging and photoacoustic imaging. With the capability for both near infrared fluorescence imaging and phototherapy, porphyrins were the first exogenous agents that were employed with intrinsic multimodal theranostic character. Porphyrins have been used as tumor-specific diagnostic fluorescence imaging agents since 1924, as positron emission agents since 1951, and as magnetic resonance (MR) contrast agents since 1987. Exogenous porphyrins remain in clinical use for photodynamic therapy. Because they can chelate a wide range of metals, exogenous porphyrins have demonstrated potential for use in radiotherapy and multimodal imaging modalities. Going forward, intrinsic porphyrin biocompatibility and multimodality will keep new applications of this class of molecules at the forefront of theranostic research.
Collapse
|
18
|
Shi J, Liu TW, Chen J, Green D, Jaffray D, Wilson BC, Wang F, Zheng G. Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. Am J Cancer Res 2011; 1:363-70. [PMID: 21938264 PMCID: PMC3177245 DOI: 10.7150/thno/v01p0363] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Accepted: 08/27/2011] [Indexed: 12/29/2022] Open
Abstract
Porphyrin based photosensitizers are useful agents for photodynamic therapy (PDT) and fluorescence imaging of cancer. Porphyrins are also excellent metal chelators forming highly stable metallo-complexes making them efficient delivery vehicles for radioisotopes. Here we investigated the possibility of incorporating (64)Cu into a porphyrin-peptide-folate (PPF) probe developed previously as folate receptor (FR) targeted fluorescent/PDT agent, and evaluated the potential of turning the resulting (64)Cu-PPF into a positron emission tomography (PET) probe for cancer imaging. Noninvasive PET imaging followed by radioassay evaluated the tumor accumulation, pharmacokinetics and biodistribution of (64)Cu-PPF. (64)Cu-PPF uptake in FR-positive tumors was visible on small-animal PET images with high tumor-to-muscle ratio (8.88 ± 3.60) observed after 24 h. Competitive blocking studies confirmed the FR-mediated tracer uptake by the tumor. The ease of efficient (64)Cu-radiolabeling of PPF while retaining its favorable biodistribution, pharmacokinetics and selective tumor uptake, provides a robust strategy to transform tumor-targeted porphyrin-based photosensitizers into PET imaging probes.
Collapse
|
19
|
Liu TW, Chen J, Burgess L, Cao W, Shi J, Wilson BC, Zheng G. Multimodal bacteriochlorophyll theranostic agent. Am J Cancer Res 2011; 1:354-62. [PMID: 21938263 PMCID: PMC3177244 DOI: 10.7150/thno/v01p0354] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2011] [Accepted: 07/30/2011] [Indexed: 01/06/2023] Open
Abstract
The complimentary ability of different noninvasive imaging technologies with therapeutic modalities can be used in tandem providing high-resolution and highly sensitive imaging of events at the molecular and cellular level providing a means for image-guided therapy. There is increasing interest in using porphyrin-based photosensitizers as theranostics to take advantages of their near-infrared fluorescent properties for imaging and their strong singlet oxygen generation abilities for photodynamic therapy. Here we report a targeted multimodal bacteriochlorophyll theranostic probe. This probe consists of a bacteriochlorophyll derivative, a pharmacokinetics modification peptide linker and folate for targeted delivery to folate receptor expressing cancer cells. We demonstrate its multimodal theranostic capability, its folate receptor targeting ability and its utility for both NIR fluorescence imaging and photodynamic therapy purposes both in vitro and in vivo.
Collapse
|
20
|
Fakhar-e-Alam M, Roohi S, Atif M, Firdous S, Amir N, Zahoor R. Labelling and optimization of PHOTOFRIN® with 99mTc. RADIOCHIM ACTA 2010. [DOI: 10.1524/ract.2010.1779] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract
PHOTOFRIN® was labelled with 99mTc using SnCl2·2H2O as reducing agent. Instant thin layer chromatography (ITLC-SG) in 0.05 M NaOH was used for evaluation of radiochemical purity. Labelling efficiency was dependent on various factors that include the ligand/reductant ratio, pH and time of incubation. Therefore, optimum conditions of labelling were also determined. The stability of 99mTc-PHOTOFRIN® in serum was checked by using fresh human serum. Tissue distribution of 99mTc-PHOTOFRIN® was evaluated in Sprague Dawley rats.
PHOTOFRIN® was labelled with an efficiency of >95% under optimum conditions, which were PHOTOFRIN®: 200 μg, pH: 3–4, SnCl2·2H2O: 15 μg and 30 min incubation at room temperature. The 99mTc-labelled PHOTOFRIN® remained stable in human serum for 24 h. Biodistribution study in rats revealed maximum concentration of the labelled compound in liver, lungs and spleen at 0.5 h, and significant activity was also seen in the bladder and urine, indicating the mode of urinary excretion of PHOTOFRIN®.
Collapse
Affiliation(s)
| | - Samina Roohi
- Pakistan Institute of Nuclear Science and Technology, Isotope Production Division, P.O. Nilore, Islamabad, Pakistan
| | | | - S. Firdous
- National Institute of Laser and Optronics, Biophotonics Laboratory, Islamabad 45650, Pakistan
| | - Nagina Amir
- Isotope Production Division, Pakistan Insititute of Nuclear Science and Technol, Islamabad, Pakistan
| | - R. Zahoor
- Pakistan Institute of Nuclear Science and Technology, Isotope Production Division, Islamabad 45650, Pakistan
| |
Collapse
|
21
|
Chemistry of Metal Radionuclides (Rb, Ga, In, Y, Cu and Tc). Mol Imaging 2009. [DOI: 10.1007/978-3-540-76735-0_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
22
|
Design considerations towards simultaneously radiolabeled and fluorescent imaging probes incorporating metallic species. ADVANCES IN INORGANIC CHEMISTRY 2009. [DOI: 10.1016/s0898-8838(09)00203-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
23
|
Kaelin AC, Zanelli GD. Synthesis and radioiodination of a meso-tetra (hydroxynaphthyl) porphyrin and its sulphonated derivative as potential tumour localizers. J Labelled Comp Radiopharm 2006. [DOI: 10.1002/jlcr.2580280311] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
24
|
Wong DW. A simple chemical method of labeling hematoporphyrin derivative with technetium-99m. J Labelled Comp Radiopharm 2006. [DOI: 10.1002/jlcr.2580200305] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
25
|
|
26
|
Affiliation(s)
- Xiankai Sun
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA
| | | |
Collapse
|
27
|
Babbar AK, Singh AK, Goel HC, Chauhan UP, Sharma RK. Evaluation of (99m)Tc-labeled photosan-3, a hematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy. Nucl Med Biol 2000; 27:587-92. [PMID: 11056374 DOI: 10.1016/s0969-8051(00)00123-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A quick and reproducible method for radiolabeling of Photosan-3(R), a photosensitizer used worldwide for photodynamic therapy (PDT) of cancer, with radioisotope of technetium ((99m)Tc) was developed. The radiotracer was evaluated for radiochemical purity, stability, and finally tissue distribution in a murine tumor model. The (99m)Tc-Photosan-3 prepared by using (99m)Tc-pertechnetate in place of reduced (99m)Tc demonstrated better labeling efficiency (>90%) and reproducibility. The procedure also minimized the radiation exposure to the radiochemist as handling time was considerably reduced. Due to the commercial availability of Photosan-3, the risk of batch-to-batch variation in the in situ synthesis of hematoporphyrin derivative, which is a complex mixture of at least five compounds, was also significantly reduced. The biodistribution studies and tumor scintigraphy confirmed that (99m)Tc-labeled Photosan-3 was preferentially taken up by the neoplastic tissue in a manner similar to the parent compound. In addition to applications in tumor imaging, (99m)Tc-Photosan-3 could also be used for estimating tumor uptake of Photosan-3 as may be required for individualization of clinical protocols of PDT.
Collapse
Affiliation(s)
- A K Babbar
- Department of Radiopharmaceuticals, Institute of Nuclear Medicine and Allied Sciences, Lucknow Marg, Delhi, India
| | | | | | | | | |
Collapse
|
28
|
Babbar AK, Singh AK, Goel HC, Chauhan UP, Sharma RK. Evaluation of (99m)Tc-labeled photosan-3, a hematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy. Nucl Med Biol 2000; 27:419-26. [PMID: 10938479 DOI: 10.1016/s0969-8051(00)00092-5] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A quick and reproducible method for radiolabeling of Photosan-3(R), a photosensitizer used worldwide for photodynamic therapy (PDT) of cancer, with radioisotope of technetium ((99m)Tc) was developed. The radiotracer was evaluated for radiochemical purity, stability, and tissue distribution in a murine tumor model. The (99m)Tc-Photosan-3, which was prepared by using (99m)Tc-pertechnetate in place of reduced (99m)Tc, demonstrated better labeling efficiency (>90%) and reproducibility. The procedure also minimized radiation exposure to the radiochemist because handling time was considerably reduced. Due to the commercial availability of Photosan-3, the risk of batch-to-batch variation in the in situ synthesis of hematoporphyrin derivative, which is a complex mixture of at least five compounds, was also significantly reduced. The biodistribution studies and tumor scintigraphy confirmed that (99m)Tc-labeled Photosan-3 was preferentially taken up by the neoplastic tissue similar to the parent compound. In addition to its applications in tumor imaging, (99m)Tc-Photosan-3 could also be used for estimating tumor uptake of Photosan-3 as may be required for individualization of clinical protocols of PDT.
Collapse
Affiliation(s)
- A K Babbar
- Department of Radiopharmaceuticals, Institute of Nuclear Medicine and Allied Sciences, Lucknow Marg, Delhi, India
| | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- H Ali
- MRC Group in the Radiation Sciences, Department of Nuclear Medicine and Radiobiology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada J1H 5N4
| | | |
Collapse
|
30
|
|
31
|
McMillan JH, Cox GG, Kimler BF, Spicer JS, Batnitzky S. Mn[III] uroporphyrin I: a novel metalloporphyrin contrast agent for magnetic resonance imaging. Magn Reson Imaging 1991; 9:553-8. [PMID: 1779726 DOI: 10.1016/0730-725x(91)90042-k] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We have used an intracranial 9L rat brain tumor model to determine whether a novel metalloporphyrin, Mn[III] uroporphyrin I (MnUROP-I), could function as an intravenous MRI contrast agent for brain tumors. In several experiments, 24 male Fischer 344 rats were inoculated intracranially with 9L brain tumor cells. On day 15 postinoculation, animals were anesthetized and the femoral vein exposed. Prior to the intravenous injection of the contrast agent, a precontrast scan (1 Tesla in a standard head coil) was performed. Thirty min after injection of the contrast agent, a postcontrast scan was performed. Although there was only a suggestion of abnormality on the precontrast scans, the presence of tumor was visibility enhanced in the postcontrast scans. In 3 animals scanned at 24 hr postinjection, persistent tumor enhancement was demonstrated. Measured tumor sizes on the MRI scans were consistent with sizes measured at autopsy and histologically. These results demonstrate that MnUROP-I is an effective MRI contrast agent for the detection of an intracranial brain tumor in the rat model.
Collapse
Affiliation(s)
- J H McMillan
- Department of Diagnostic Radiology, University of Kansas Medical Center, Kansas City 66103
| | | | | | | | | |
Collapse
|
32
|
Abstract
Photofrin II (dihaematoporphyrin ether/ester, DHE) was labelled with indium-111 and its biodistribution in tumour bearing mice compared with that of 111In chloride. The uptake and clearance of 111In labelled DHE differed markedly from that of indium-111 chloride in that the former was not taken up by the tissues as much as the latter. Scintillation scanning with a gamma-camera showed marked uptake of both 111In agents at the site of the tumour, but a much lower tissue background (excluding the abdominal organs) for the mice given 111In DHE. Tumour:muscle ratios of dissected tissues were 2-3 times higher in 111In DHE treated animals as compared to the uptake of 111In chloride. There was a distinct difference in the pattern of distribution of the two 111In preparations in the tissues. The major accumulation of 111In chloride was in the kidneys, whereas the highest uptake of 111In DHE was in the liver, the organ in which unlabelled porphyrins accumulate. Extraction and testing of materials from tumours of 111In DHE treated animals indicated that most of the tumour extractable 111In had remained associated with the porphyrin in vivo up to 4 days after injection.
Collapse
Affiliation(s)
- M R Quastel
- Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel
| | | | | |
Collapse
|
33
|
Wong DW, Mandal A, Brown J, Reese IC, Siegler R, Hyman S. In vivo assessment of 111In-labeled hematoporphyrin derivative in breast tumor-bearing animals. INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION. PART B, NUCLEAR MEDICINE AND BIOLOGY 1989; 16:269-81. [PMID: 2523878 DOI: 10.1016/0883-2897(89)90008-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The biological behavior of 111In-labeled HPD has been investigated in tumor-bearing animals. Mice mammary adenocarcinomas and 7,12-dimethylbenz(a)anthracine induced breast tumors in Sprague-Dawley female rats were clearly visualized by 111In-HPD nuclear scintigraphy. Optimal scans were obtained after a 48 h delay. In normal and tumor-bearing animals, the highest uptake of 111In-HPD 72 h post-injection was found in the liver, the spleen and the kidneys. Depending on the size and the extent of necrosis, the uptake of 111In-HPD by malignant breast tumors varied from 2.5% injected dose (ID) (range 0.14-5.3% ID) in mice to 1% (range 0.22-8.1% ID) in rats. Benign breast tumor uptake of 111In-HPD was less than 1% ID. No significant amount of the radiopharmaceutical was found in pulmonary abscesses and abdominal cysts (less than 0.1% ID). Scintigrams of these infectious or inflammatory lesions were normal. Malignant tumor to blood, heart and lung ratios averaged 50:1, 10:1 and 3:1 respectively. Tumor to brain ratio ranged from 72 to 444:1.
Collapse
Affiliation(s)
- D W Wong
- Department of Radiology, King/Drew Medical Center, U.C.L.A. 90059
| | | | | | | | | | | |
Collapse
|
34
|
Thaller RA, Lyster DM, Dolphin D. Potential use of radiolabelled porphyrins for tumor scanning. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1983; 160:265-78. [PMID: 6220576 DOI: 10.1007/978-1-4684-4406-3_23] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Fe-TMPI, Fe-TCP and protohemins showed high initial uptake using tissue culture techniques with mouse tumor cells (P815). However, the tumor uptake in the in vivo model was poor. Of the radionuclides investigated, iron labelled to TMPI demonstrated the best uptake by tumor in vitro. As has been previously demonstrated, the unnatural meso-arylporphyrin derivatives showed better uptake than did naturally occurring porphyrins and their derivatives.
Collapse
|
35
|
Wong DW, Mandal A, Reese IC, Brown J, Siegler R. In vivo assessment of 99mTc-labeled hematoporphyrin derivative in tumor-bearing animals. INTERNATIONAL JOURNAL OF NUCLEAR MEDICINE AND BIOLOGY 1983; 10:211-8. [PMID: 6319312 DOI: 10.1016/0047-0740(83)90081-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The efficacy of 99mTc-labeled hematoporphyrin derivative in localizing neoplasms has been investigated with tumor-bearing animal models. Spontaneous mammary adenocarcinomas of outbred CFW strain Swiss-Webster white mice and chemical carcinogen induced breast tumors in female Sprague-Dawley white rats were clearly visualized in the scintigrams. Mice tissue distribution data demonstrate favourable tumor to organ ratios sufficiently high to permit tumor detection. [99mTc]HPD appears promising as a tumor imaging agent.
Collapse
|
36
|
King EG, Doiron D, Man G, Profio AE, Huth G. Hematoporphyrin derivative as a tumor marker in the detection and localization of pulmonary malignancy. Recent Results Cancer Res 1982; 82:90-6. [PMID: 7111845 DOI: 10.1007/978-3-642-81768-7_9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
37
|
Bassel J, Hambright P, Mortimer R, Bearden AJ. Mutant of the yeast Saccharomycopsis lipolytica that accumulates and excretes protorphyrin IX. J Bacteriol 1975; 123:118-22. [PMID: 1141193 PMCID: PMC235697 DOI: 10.1128/jb.123.1.118-122.1975] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The red, water-insoluble pigment excreted by a mutant strain of the yeast Saccharomycopsis lipolytica is show to be protoporphyrin IX. In genetic crosses the red phenotype has the properties characteristic of a defect in a single, recessive nuclear gene. The yield and ease of harvest of protoporphyrin IX from the yeast mutant indicate that this strain or its derivatives may be a valuable source of this substance.
Collapse
|
38
|
Tsutsui M, Carrano C, Tsutsui EA. Tumor localizers: porphyrins and related compounds (unusual metalloporphyrins XXIII). Ann N Y Acad Sci 1975; 244:674-84. [PMID: 1094888 DOI: 10.1111/j.1749-6632.1975.tb41561.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
39
|
Hambright P, Fawwaz R, Valk P, McRae J, Bearden AJ. The distribution of various water soluble radioactive metalloporphyrins in tumor bearing mice. BIOINORGANIC CHEMISTRY 1975; 5:87-92. [PMID: 1182211 DOI: 10.1016/s0006-3061(00)80224-0] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
40
|
Fawwaz RA, Tenforde TS. Tumor diagnosis using short-lived radioactive compounds: a new approach. Med Hypotheses 1975; 1:29-31. [PMID: 1202324 DOI: 10.1016/0306-9877(75)90038-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
41
|
Gregorie HB, Horger EO, Ward JL, Green JF, Richards T, Robertson HC, Stevenson TB. Hematoporphyrin-derivative fluorescence in malignant neoplasms. Ann Surg 1968; 167:820-8. [PMID: 5690034 PMCID: PMC1387148 DOI: 10.1097/00000658-196806000-00002] [Citation(s) in RCA: 179] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
42
|
Datta-Gupta N, Bardos TJ. Synthetic porphyrins. II. Preparation and spectra of some metal chelates of para-substituted-meso-tetraphenylporphines. J Pharm Sci 1968; 57:300-4. [PMID: 5641674 DOI: 10.1002/jps.2600570211] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
43
|
Winkelman J. Metabolic studies on the accumulation of tetraphenylporphinesulfonate in tumours. EXPERIENTIA 1967; 23:949-50. [PMID: 4168179 DOI: 10.1007/bf02136242] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
44
|
Cunningham RD, Henderson JW. Experimental evaluation of hematoporphyrin in the detection and management of intraocular tumors. Am J Ophthalmol 1966; 61:36-44. [PMID: 5904377 DOI: 10.1016/0002-9394(66)90744-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
45
|
Vincent PC. THE MANAGEMENT OF THE PATIENT WITH INOPERABLE MALIGNANT DISEASE. Med J Aust 1963. [DOI: 10.5694/j.1326-5377.1963.tb23532.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- P. C. Vincent
- Wellcome Research LaboratoryRoyal North Shore Hospital Sydney
| |
Collapse
|
46
|
|
47
|
BASES R, PEARLMAN A, ROSH R, RUBENFELD S. Attempts at modification of the radiation response of neoplasms by the administration of “hematoporphyrin”. Cancer 1958; 11:1119-24. [PMID: 13608411 DOI: 10.1002/1097-0142(195811/12)11:6<1119::aid-cncr2820110606>3.0.co;2-k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|